As oncology drugs receive accelerated approvals, payers are questioning whether the benefits of these products outweigh the cost, spurring manufacturers to explore value-based agreements.
https://www.pharmalive.com/wp-content/uploads/2023/02/melanoma.jpg686500Christiane Truelovehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngChristiane Truelove2023-02-14 07:00:152023-05-11 21:20:46The value of oncology drugs
